Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Completed
National Cancer Institute (NCI)
Phase 2
2007-01-01
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged
skin.
PURPOSE: This randomized phase II trial is studying the side effects and how well
eflornithine works compared with diclofenac, given alone or together, in treating patients
with sun-damaged skin.
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Completed
University of Arizona
Phase 2
2007-01-01
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
of eflornithine and diclofenac may stop cancer from growing in patients with sun-damaged
skin.
PURPOSE: This randomized phase II trial is studying the side effects and how well
eflornithine works compared with diclofenac, given alone or together, in treating patients
with sun-damaged skin.
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
Completed
Bispebjerg Hospital
Phase 4
2012-01-01
Split-face investigation of the efficacy of applying Eflornithin cream twice daily for six
months after a period with six laser treatments for hair removal.
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Active, not recruiting
National Cancer Institute (NCI)
Phase 2
2019-05-28
This phase II trial studies how well irinotecan hydrochloride, temozolomide, and dinutuximab
work with or without eflornithine in treating patients with neuroblastoma that has come back
(relapsed) or that isn't responding to treatment (refractory). Drugs used in chemotherapy,
such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Immunotherapy with monoclonal antibodies, such as dinutuximab, may
induce changes in the body's immune system and may interfere with the ability of tumor cells
to grow and spread. Eflornithine blocks the production of chemicals called polyamines that
are important in the growth of cancer cells. Giving eflornithine with irinotecan
hydrochloride, temozolomide, and dinutuximab, may work better in treating patients with
relapsed or refractory neuroblastoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
